cemiplimab
cemiplimab: 86 clinical trials tracked.
cemiplimab evidence translation
What we can confirm
86 tracked trials
What it means
What to watch
Prepared research question
What is verified about cemiplimab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 17 study sponsors
Related indications
Clinical Trials (86)showing 10 most recent
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Primary endpoint: Pathologic Complete Response Rate
A Phase 2 Study of Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC-2)
Primary endpoint: Overall response rate (ORR)
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
Primary endpoint: Major pathologic response (MPR)
Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)
Primary endpoint: Rate of pathologic downstaging
A Pilot Randomized Trial of Induction Cemiplimab With or Without Fianlimab in De-escalated Chemoradiation for Locoregionally Advanced Non-Metastatic Nasopharyngeal Carcinoma
Primary endpoint: Complete response rate
A Randomized Phase II Study of the Efficacy of Laser Interstitial Thermal Therapy (LiTT) Combined With Cemiplimab Versus Physician's Choice Chemotherapy in Recurrent Glioblastomas
Primary endpoint: Progression-free survival (PFS) at Month 6 (PFS6)
A Phase 2 Single-arm Study of Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement or Other High Risk Features
Primary endpoint: Pathologic complete response (pCR) rate
A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer
Primary endpoint: Progression free survival (PFS)
Combining Capecitabine/Oxaliplatin Chemotherapy With Cemiplimab Alone or in Combination With Fianlimab or REGN7075 for the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Primary endpoint: Pathologic complete response (pCR) rate
A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma
Primary endpoint: Dose limiting toxicities (DLTs)